Why Ancestry Matters in the Cardiac Screening of Elite Soccer Players

Why It Matters

Treating Black athletes as a monolithic group masks critical ancestry‑related risk differences, potentially compromising early detection of life‑threatening cardiac conditions.

Key Takeaways

• 25% of screened players identified as Black, 9,024 total
• West and Central African players show highest ECG abnormalities
• Hypertrophic cardiomyopathy found in 1% of Black versus 0.4% non‑Black
• North African players' cardiac profiles similar to non‑Black athletes
• Study suggests ancestry‑specific screening could improve detection efficiency

Pulse Analysis

Sudden cardiac death (SCD) remains a rare but devastating outcome in elite sport, prompting mandatory cardiovascular screening for professional footballers. Historically, screening protocols have grouped athletes of Black ethnicity together, relying on broad risk estimates that overlook the genetic and physiological diversity within this population. Recent advances in sports cardiology emphasize precision medicine, urging clinicians to consider finer demographic variables—such as regional ancestry—to enhance diagnostic accuracy and protect high‑performance athletes.

The ESC Preventive Cardiology 2026 cohort, encompassing over nine thousand English Football Association players, provides the most extensive dataset to date on ancestry‑related cardiac variation. Researchers identified that players of West and Central African descent exhibited the steepest prevalence of T‑wave inversions and left‑ventricular remodeling, markers linked to arrhythmic risk. By contrast, North African athletes showed ECG and echocardiographic patterns comparable to their non‑Black counterparts. The study also highlighted a two‑fold increase in hypertrophic cardiomyopathy among Black players, driven primarily by those of West African origin. These granular insights challenge the one‑size‑fits‑all approach and suggest that tailored ECG interpretation criteria could reduce false‑positive referrals while catching genuine pathology earlier.

If governing bodies integrate ancestry‑specific thresholds into pre‑participation examinations, clubs could allocate medical resources more efficiently and potentially lower the incidence of SCD. However, operationalizing such stratification requires robust training for sports physicians, standardized ancestry questionnaires, and ethical safeguards to prevent discrimination. Ongoing research will need to validate these findings across other leagues and sports, but the current evidence positions ancestry‑aware screening as a promising evolution in athlete health management, aligning clinical practice with the broader move toward personalized medicine.